Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chemotherapy given directly to the liver improves survival for patients with colorectal cancer

28.02.2006


A new study shows that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI)-- the administration of chemotherapy directly to the liver through a pump in the abdomen--fare better than those who received traditional, intravenous chemotherapy. Researchers found that the patients on the HAI therapy lived longer and had better quality of life than those receiving systemic therapy. The study will be published online February 27 in the Journal of Clinical Oncology.



"This study demonstrates that hepatic arterial infusion therapy extends survival and improves quality of life in patients with colorectal cancer that has spread to the liver," said Nancy E. Kemeny, MD, an Attending Physician in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the study’s lead author. "These positive findings are particularly important, given that metastasis to the liver occurs in 60% of patients with metastatic colorectal cancer, and most patients with these liver tumors eventually die of their disease."

Several smaller studies have previously compared outcomes of HAI with systemic chemotherapy, but this is the first large study that had no crossover between the groups, meaning that none of the patients in the systemic group received HAI therapy.


In the multi-institutional trial by researchers from the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group, 135 patients were assigned randomly to receive either HAI or systemic chemotherapy. All of the patients needed to undergo surgical removal (resection) of their primary tumors in the colon or rectum before initiating chemotherapy. Patients receiving HAI then underwent a surgical procedure to have a chemotherapy pump inserted into their abdomen. (This procedure can sometimes be done laparoscopically.)

Researchers found that patients receiving HAI lived longer than those receiving systemic chemotherapy, with a median survival of 24 versus 20 months. In addition, patients receiving HAI had better response rates (47% versus 24%), and longer time to disease progression in the liver (9.8 months versus 7.3 months).

While patients receiving systemic chemotherapy experienced the usual treatment-associated side effects such as diarrhea, decreased white blood cell counts, and hair loss, patients receiving HAI did not. However, because patients on the HAI regimen experienced mild toxicity to the liver, patients’ liver functions were monitored closely throughout the duration of treatment to prevent the toxicity from becoming more severe.

For both methods of treatment, women fared better than men, with median survival in the HAI group of 29.4 and 20.1 months for women and men, respectively, and in the systemic group it was 22.0 and 18.3 months.

Because the research began in 1996, before chemotherapy drugs such as irinotecan and oxaliplatin were available, both sets of patients received fluorouracil and leucovorin. Both groups had access to the newer drugs as they became available. Dr. Kemeny noted that studies are currently underway using HAI therapy in combination with newer drugs, and response rates appear to be even higher. Furthermore, the addition of HAI therapy is also being investigated in patients with primary liver cancer.

Danielle Potuto | EurekAlert!
Further information:
http://www.asco.org

More articles from Studies and Analyses:

nachricht The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Previous evidence of water on mars now identified as grainflows

21.11.2017 | Physics and Astronomy

NASA's James Webb Space Telescope completes final cryogenic testing

21.11.2017 | Physics and Astronomy

New catalyst controls activation of a carbon-hydrogen bond

21.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>